On December 1, 2015 Genmab A/S (Nasdaq Copenhagen: GEN) reported it will hold its annual R&D Update focused on the company’s latest developments in antibody innovation on December 8, 2015 from 8:00 PM to 10:00 PM CET (Press release, Genmab, DEC 1, 2015, View Source [SID:1234508372]). The update will include presentations by key opinion leaders describing data from studies of daratumumab presented at the 57th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) as well as information on Genmab’s pipeline product HuMax-TF-ADC. Genmab will also discuss the company’s pre-clinical pipeline, the proprietary DuoBody and HexaBody technologies and will present its 2016 Key Goals.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following cancer experts and senior Genmab staff will attend the event:
Daratumumab Key Opinion Leaders:
Professor Thierry Facon, Professor of Hematology, Head of the Department of Hematology, Lille University Hospital, Lille, France
Professor Maria Victoria Mateos, Associate Professor of Medicine, University Hospital of Salamanca, Salamanca, Spain
Professor Torben Plesner, Department of Hematology, Vejle Hospital, Vejle, Denmark
Dr. Peter Voorhees, M.D., Associate Professor, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US
HuMax-TF-ADC Key Opinion Leader:
Professor Johann de Bono, Director of the Drug Development Unit & Head of Prostate Cancer Targeted Therapy Group, Professor of Experimental Cancer Medicine & Honorary Consultant in Medical Oncology, The Institute of Cancer Research, Surrey, UK
Genmab:
Dr. Jan van de Winkel, President and CEO, Genmab
David Eatwell, Executive Vice President and CFO, Genmab
ASH abstracts to be discussed during the event include:
Management of Infusion-related Reactions Following Daratumumab Monotherapy in Patients with ≥3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)
Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results from a Phase 1/2 Study (GEN503)
Open-label, Multicenter Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with ≥2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
The R&D Update is taking place at the Hyatt Regency Orlando in Orlando, Florida. Those wishing to attend in person should email [email protected]
The event can be attended via webcast. To view this webcast visit: View Source Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab’s website. The webcast will be conducted in English.
This meeting is not an official program of the ASH (Free ASH Whitepaper) Annual Meeting.